CleveMed Issued a Seminal Patent in Home Sleep Testing

US Patent “Method and device for sleep analysis” covers the collection of patient data from standard home sensors and the data transfer using internet, cellular, or wired-network methodologies among others.

Cleveland, OH – July 31, 2018 – Cleveland Medical Devices Inc. (CleveMed), a leader in home sleep apnea testing technologies was just issued a new patent (US Patent No. 10,028,698) entitled “Method and device for sleep analysis”. The patent covers the collection of patient data from standard home sensors and the data transfer using internet, cellular or wired-network methodologies among others.

Home Sleep Testing (HST) is quickly becoming the standard method to diagnose patients with obstructive sleep apnea with hundreds of thousands of studies done each year. High patient demand combined with a physicians’ shortage are driving many equipment manufacturers and healthcare systems to implement methods that facilitate remote online access to data and analysis. “CleveMed is very excited about this patent and believes it will lead to significant licensing opportunities in the near-term, especially when one considers the ongoing HST growth. A good licensing program for this technology will also lower the costs of patient diagnosis while more importantly, due to data consolidation as part of this program, will allow further therapy cost reductions and improved choices to patients and their insurers”, said Dr. Brian Kolkowski, CleveMed Executive Vice President and General Counsel.

“Nearly a decade and a half ago, we began development of data transfer technologies and pursued a focused patent strategy to improve access of home sleep data from anywhere. These techniques are now common practice in the marketplace, which position CleveMed at a unique advantage over the competition not only in current HST markets but in new areas including Big Data analytics. We aim to expand Big Data, which is typically based on hospital sleep information, to include extensive home-based data”. Said Hani Kayyali, CleveMed CEO.

Obstructive sleep apnea (OSA), the most prevalent form of sleep apnea, is a repeated interruption of normal breathing during sleep due to a collapse of the upper airway. It is estimated to impact as many people as asthma and diabetes; yet, up to 80 percent of the population with the disease remain undiagnosed and untreated. Moreover, OSA leads to serious health and economic consequences. Numerous studies link OSA to major chronic diseases such as stroke, heart failure, diabetes, obesity, hypertension and increased odds of serious car crash injuries.

CleveMed is a fast growing company with a wide range of sleep testing equipment, fulfillment services, and cloud based technologies that allow sleep disorders to be monitored in the home, including Sapphire PSG™, SleepView®, SleepViewSM Web-portal, and SleepView Direct. CleveMed’s goal is to expand the reach of sleep medicine with technologies that speed diagnosis for providers, reduce healthcare costs for payers, and improve patients’ experiences in the home. For more information, please visit https://CleveMed.com (Follow us on twitter, youtube, LinkedIn, and facebook). SleepView is a registered trademark and a service mark, and Sapphire PSG is a trademark of Cleveland Medical Devices Inc. of Cleveland, OH.

July 31st, 2018|